SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.9158

Change

-0.06 (-6.55)%

Market Cap

N/A

Volume

1.61M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.60 (-0.77%)

USD 246.02B
AMGN Amgen Inc

-2.21 (-0.69%)

USD 171.76B
SNY Sanofi ADR

-0.71 (-1.28%)

USD 145.06B
GILD Gilead Sciences Inc

-0.16 (-0.19%)

USD 105.31B
BIIB Biogen Inc

-2.34 (-1.26%)

USD 27.05B
GRFS Grifols SA ADR

-0.04 (-0.45%)

USD 7.08B
AMRN Amarin Corporation PLC

-0.03 (-4.89%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.03 (-2.61%)

USD 0.02B
SCLXW Scilex Holding Company

N/A

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -55.11% 20% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.11% 20% F 13% F
Trailing 12 Months  
Capital Gain -49.68% 40% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.68% 40% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector